Dipeptidyl peptidase-4 inhibition by Pterocarpus marsupium and Eugenia jambolana ameliorates streptozotocin induced Alzheimer's disease

Behavioural Brain Research

Volumn 267, Issue , 2014, Pages 55-65

  Kosaraju, Jayasankar ^a   Madhunapantula, SubbaRao V ^b   Chinni, Santhivardhan ^a   Khatwal, Rizwan Basha ^a   Dubala, Anil ^a   Muthureddy Nataraj, Satish Kumar ^a   Basavan, Duraiswamy ^a  

^a JSS COLLEGE OF PHARMACY   (India)

^b JSS MEDICAL COLLEGE   (India)

Author keywords

Amyloid load; Eugenia jambolana; Glucagon like peptide 1; Neuro inflammation; Pterocarpus marsupium; Tau phosphorylation

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; KINO EXTRACT; PLANT EXTRACT; STREPTOZOCIN; SYZYGIUM CUMINI EXTRACT; TAU PROTEIN; UNCLASSIFIED DRUG; VILDAGLIPTIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); DIPEPTIDYL PEPTIDASE IV INHIBITOR; MAPT PROTEIN, RAT; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT; PLANT MEDICINAL PRODUCT;

ADULT; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME INHIBITION; HOLE BOARD TEST; KINO; MALE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PTEROCARPUS; RADIAL ARM MAZE TEST; RAT; RAT MODEL; SYZYGIUM CUMINI; TREATMENT DURATION; WISTAR RAT; ANIMAL; COGNITION DISORDERS; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; EUGENIA; HIPPOCAMPUS; MAZE TEST; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYTOTHERAPY; PLAQUE, AMYLOID; TIME;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; COGNITION DISORDERS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EUGENIA; GLUCAGON-LIKE PEPTIDE 1; HIPPOCAMPUS; MALE; MAZE LEARNING; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PHYTOTHERAPY; PLANT PREPARATIONS; PLAQUE, AMYLOID; PTEROCARPUS; RATS, WISTAR; STREPTOZOCIN; TAU PROTEINS; TIME FACTORS;

EID: 84897429031     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.03.026     Document Type: Article

References (46)

1. Thies W., Bleiler L., Alzheimer's Association 2013 Alzheimer's disease facts and figures. Alzheimers Dement 2013, 9:208-245.
2. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
3. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. J Am Med Assoc 2004, 291:317-324.
4. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., Mobius H.J. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003, 348:1333-1341.
5. Grutzendler J., Morris J.C. Cholinesterase inhibitors for Alzheimer's disease. Drugs 2001, 61:41-52.
6. Kosaraju J., Dubala A., Chinni S., Khatwal R.B., Satish Kumar M.N., Basavan D. A molecular connection of Pterocarpus marsupium, Eugenia jambolana and Gymnema sylvestre with dipeptidyl peptidase-4 in the treatment of diabetes. Pharm Biol 2014, 52:268-271.
7. Kosaraju J., Gali C.C., Khatwal R.B., Dubala A., Chinni S., Holsinger R.M., et al. Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease. Neuropharmacology 2013, 72:291-300.
8. Kosaraju J., Murthy V., Khatwal R.B., Dubala A., Chinni S., Muthureddy Nataraj S.K., et al. Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease. J Pharm Pharmacol 2013, 10.1111/jphp.12148.
9. Grunblatt E., Salkovic-Petrisic M., Osmanovic J., Riederer P., Hoyer S. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 2007, 101:757-770.
10. Lester-Coll N., Rivera E.J., Soscia S.J., Doiron K., Wands J.R., de la Monte S.M. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis 2006, 9:13-33.
11. de la Monte S.M., Wands J.R. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis 2005, 7:45-61.
12. Baek I.S., Kim T.K., Seo J.S., Lee K.W., Lee Y.A., Cho J., et al. AAD-2004 attenuates progressive neuronal loss in the brain of Tg-betaCTF99/B6 mouse model of Alzheimer disease. Exp Neurobiol 2013, 22:31-37.
13. Remsberg C.M., Yáñez J.A., Roupe K.A., Davies N.M. High-performance liquid chromatographic analysis of pterostilbene in biological fluids using fluorescence detection. J Pharm Biomed Anal 2007, 43:250-254.
14. Ravi K., Ramachandran B., Subramanian S. Protective effect of Eugenia jambolana seed kernel on tissue antioxidants in streptozotocin-induced diabetic rats. Biol Pharm Bull 2004, 27:1212-1217.
15. Lei F., Xing D.M., Xiang L., Zhao Y.N., Wang W., Zhang L.J., et al. Pharmacokinetic study of ellagic acid in rat after oral administration of pomegranate leaf extract. J Chromatogr B: Analyt Technol Biomed Life Sci 2003, 796:189-194.
16. Ainsworth E.A., Gillespie K.M. Estimation of total phenolic content and other oxidation substrates in plant tissues using Folin-Ciocalteu reagent. Nat Protoc 2007, 2:875-877.
17. Sehgal N., Gupta A., Valli R.K., Joshi S.D., Mills J.T., Hamel E., et al. Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci USA 2012, 109:3510-3515.
18. Froelich L., Ding A., Hoyers S. Holeboard maze-learning deficits and brain monoaminergic neurotransmitter concentrations in rats after intracerebroventricular injection of 3-Bromopyruvate. Pharmacol Biochem Behav 1995, 51:917-922.
19. Park O.K., Choi J.H., Park J.H., Kim I.H., Yan B.C., Ahn J.H., et al. Comparison of neuroprotective effects of five major lipophilic diterpenoids from Danshen extract against experimentally induced transient cerebral ischemic damage. Fitoterapia 2012, 83:1666-1674.
20. Green B.D., Peter R.F., Clifford J.B. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res 2006, 3:159-165.
21. Kastin A.J., Akerstrom V., Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002, 18:7-14.
22. Hamilton A., Holscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 2009, 20:1161-1166.
23. Holscher C. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Pat CNS Drug Discov 2010, 5:109-117.
24. Chen S., Liu A.R., An F.M., Yao W.B., Gao X.D. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4. Age (Dordr) 2012, 34:1211-1224.
25. 8) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains. Eur J Pharmacol 2012, 674:280-286.
26. Gengler S., McClean P.L., McCurtin R., Gault V.A., Holscher C. Val(8) GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging 2010, 33:265-276.
27. Yamazaki K., Yasuda N., Inoue T., Nagakura T., Kira K., Shinoda M., et al. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9- dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity. J Pharmacol Exp Ther 2006, 319:1253-1257.
28. Perry T., Greig N.H. The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. J Alzheimers Dis 2002, 4:487-496.
29. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003, 9:1173-1179.
30. Salkovic-Petrisic M., Osmanovic J., Grunblatt E., Riederer P., Hoyer S. Modeling sporadic Alzheimer's disease: the insulin resistant brain state generates multiple long-term morphobiological abnormalities including hyperphosphorylated tau protein and amyloid-beta. J Alzheimers Dis 2009, 18:729-750.
31. Jarrett J.T., Berger E.P., Lansbury P.T. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993, 32:4693-4697.
32. El-Agnaf O.M., Mahil D.S., Patel B.P., Austen B.M. Oligomerization and toxicity of beta-amyloid-42 implicated in Alzheimer's disease. Biochem Biophys Res Commun 2000, 273:1003-1007.
33. D'Amico M., Di Filippo C., Marfella R., Abbatecola A.M., Ferraraccio F., Rossi F., et al. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Exp Gerontol 2010, 45:202-207.
34. Mandelkow E., Song Y.H., Schweers O., Marx A., Mandelkow E.M. On the structure of microtubules, tau, and paired helicalfilaments. Neurobiol Aging 1995, 16:347-354.
35. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., Laferla F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004, 43:321-332.
36. Sharma M., Gupta Y.K. Intrecerbroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment. Life Sci 2001, 68:1021-1029.
37. Sharma B., Singh N., Singh M. Modulation of celecoxib- and streptozotocin-induced experimental dementia of Alzheimer's disease by Pitavastatin and Donepezil. J Psychopharmacol 2008, 22:162-171.
38. Tiwari V., Kuhad A., Bishnoi M., Chopra K. Chronic treatment with Tocotrienol, an isoform of vitamin E, prevents intracerebroventricular streptozotocin-induced cognitive impairment and oxidative-nitrosative stress in rats. Pharmacol Biochem Behav 2009, 93:183-189.
39. Tota S., Kamat P.K., Shukla R., Nath C. Improvement of brain energy metabolism and cholinergic functions contributes to the beneficial effects of silibinin against streptozotocin induced memory impairment. Behav Brain Res 2011, 221:207-215.
40. Abrahams S., Morris R.G., Polkey C.E., Jarosz J.M., Cox T.C., Graves M., et al. Hippocampal involvement in spatial and working memory: a structural MRI analysis of patients with unilateral mesial temporal lobe sclerosis. Brain Cogn 1999, 41:39-65.
41. Wang Y.J., Thomas P., Zhong J.H., Bi F.F., Kosaraju S., Pollard A., et al. Consumption of grape seed extract prevents amyloid-β deposition and attenuates inflammation in brain of an Alzheimer's disease mouse. Neurotox Res 2009, 15:3-14.
42. Prakash A.K., Kumar A. Effect of chronic treatment of carvedilol on oxidative stress in an intracerebroventricular streptozotocin induced model of dementia in rats. J Pharm Pharmacol 2009, 61:1665-1672.
43. Dickson D.W. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997, 56:321-339.
44. Apelt J., Schliebs R. Beta-amyloid-induced glial expression of both pro- and anti- inflammatory cytokines in cerebral cortex of aged and transgenic transgenicTg2576 mice with Alzheimer plaque pathology. Brain Res 2001, 894:21-30.
45. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response. Nat Med 2006, 12:1005-1015.
46. Shiraki A., Oyama J., Komoda H., Asaka M., Komatsu A., Sakuma M., et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 2012, 221:375-382.